Opendata, web and dolomites

HypoCyclo SIGNED

Multifunctional Polymeric Cyclodextrin Nanocarriers As Novel Triple-Negative Breast Cancer Treatment: A Versatile Photo-Chemotherapy Bypassing Hypoxic Conditions

Total Cost €


EC-Contrib. €






 HypoCyclo project word cloud

Explore the words cloud of the HypoCyclo project. It provides you a very rough idea of what is the project "HypoCyclo" about.

worldwide    demanding    treatment    therapeutic    binding    technological    ros    triple    collaborating    synthesis    presenting    agents    situ    independent    green    light    cancers    assays    solubilize    option    release    compromises    upgrade    2d    negative    seeking    foresees    source    industrial    photodynamic    tnbc    generate    operative    limited    encapsulate    vitro    protocols    supervisor    20    sme    nanoparticles    feasible    aggressive    loaded    cyd    decorated    therapy    training    tailor    covalent    innovative    subtype    keep    tested    tissue    chemotherapy    releasing    researcher    ora    cyclolab    synthetic    paclitaxel    represented    successful    respectively    insolubility    multimodal    guaranteeing    female    solid    poor    completely    hypocyclo    optics    polymer    population    standard    biological    3d    endowed    give    species    reactive    drug    cancer    biocompatible    therapies    nps    optimal    efficacy    envisage    photosensitizer    load    thanks    pdt    models    pcx    er    antitumor    options    oxygen    cells    interstitial    complete    decoration    alternative    cyclodextrin    combination    bc    hypoxia    mixed    unibo    polymers    agent    fiber    polymeric    outcome    lasers    survival    profile    breast    ps    tumours    water   

Project "HypoCyclo" data sheet

The following table provides information about the project.


Organization address
city: ROMA
postcode: 185

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 257˙209 €
 EC max contribution 257˙209 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-CAR
 Starting year 2020
 Duration (year-month-day) from 2020-09-01   to  2023-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Among all breast cancers (BC) affecting female population worldwide, 20% is represented by Triple Negative Breast Cancer (TNBC), an aggressive subtype with very limited therapeutic options and poor survival. Seeking for innovative TNBC therapies, HypoCyclo aims at the optimal combination of chemotherapy and photodynamic therapy (PDT). We envisage novel, tailored cyclodextrin (CyD)-based polymeric nanoparticles (NPs) able to load “known” therapeutic agents and decorated with a photosensitizer as well as an Oxygen-Releasing Agent. HypoCyclo focuses on the very effective drug paclitaxel (PCX) presenting several treatment problems like water insolubility. Biocompatible, novel CyD polymers are expected to solubilize and encapsulate through non-covalent binding the drug of choice in order to implement PCX chemotherapy with PDT, through the decoration with a PS able to generate antitumor reactive oxygen species (ROS) in situ. Indeed, PDT has become a very challenging yet feasible option thanks to the technological advances in lasers and fiber-optics allowing interstitial and intra-operative light delivery for the treatment of solid tumours, including BC. Finally, as hypoxia in BC tissue compromises standard chemotherapy and PDT, we will tailor our NPs with an ORA able to release oxygen in cells, enabling an alternative ROS source. The PCX loaded NPs will be completely characterized and tested in 2D and 3D TNBC models. Our goal is to keep the synthetic protocols simple, low-cost and green to facilitate industrial upgrade of the loaded multimodal NPs endowed with improved in vitro efficacy. Two partners, the SME Cyclolab and UNIBO, both already collaborating with the supervisor, will give the necessary support in mixed-CyD polymer synthesis and in the biological assays, respectively, guaranteeing a successful outcome. The project foresees a demanding training program for ER that will help him to become an independent researcher with a complete profile.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYPOCYCLO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYPOCYCLO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NeoPur (2019)

New treatments and novel diagnostic tests for neonatal seizures based on purinergic signaling.

Read More  

DEMOS (2019)

Disfluencies and Eye MOvements during Speech: what can they reveal about language production?

Read More  

EPIC (2019)

Evolution of Planktonic Gastropod Calcification

Read More